About: Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience
Creator	Tamm, Michael Hirsch, Hans Tschudin-Sutter, Sarah Baettig, Veronika Compagno, Francesca Gerull, Sabine Halter, Jörg Khanna, Nina Passweg, Jakob Spahr, Yasmin
Source	Medline; PMC
abstract	BACKGROUND: Paramyxoviruses include respiratory syncytial virus (RSV), parainfluenza virus (PIV), and human metapneumovirus (MPV), which may cause significant respiratory tract infectious disease (RTID) and mortality after allogeneic hematopoietic cell transplantation (HCT). However, clinical data regarding frequency and outcome are scarce. METHODS: We identified all paramyxovirus RTIDs in allogeneic HCT recipients diagnosed by multiplex polymerase chain reaction between 2010 and 2014. Baseline characteristics of patients, treatment, and outcome of each episode were analyzed; ie, moderate, severe, and very severe immunodeficiency (verySID) according to HCT ≤6 months, T- or B-cell depletion ≤3 months, graft-versus-host disease, neutropenia, lymphopenia, or hypo-gammaglobulinemia. RESULTS: One hundred three RTID episodes in 66 patients were identified (PIV 47% [48 of 103], RSV 32% [33 of 103], MPV 21% [22 of 103]). Episodes occurred in 85% (87 of 103) at >100 days post-HCT. Lower RTID accounted for 36% (37 of 103). Thirty-nine percent (40 of 103) of RTID episodes required hospitalization and more frequently affected patients with lower RTID. Six percent progressed from upper to lower RTID. Overall mortality was 6% and did not differ between paramyxoviruses. Sixty-one percent (63 of 103) of episodes occurred in patients with SID, and 20.2% (19 of 63) of episodes occurred in patients with verySID. Oral ribavirin plus intravenous immunoglobulin was administered in 38% (39 of 103) of RTIDs, preferably for RSV or MPV (P ≤ .001) and for SID patients (P = .001). Patients with verySID frequently progressed to lower RTID (P = .075), required intensive care unit transfer, and showed higher mortality. CONCLUSION: Paramyxovirus RTID remains a major concern in allogeneic HCT patients fulfilling SID and verySID, emphasizing that efficacious and safe antiviral treatments are urgently needed.
has issue date	2018-04-12(xsd:dateTime)
bibo:doi	10.1093/ofid/ofy077
bibo:pmid	29780847
has license	cc-by-nc-nd
sha1sum (hex)	b8991fb0bcc563dc28c736e05639bc604f611e84
schema:url	https://doi.org/10.1093/ofid/ofy077
resource representing a document's title	Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience
has PubMed Central identifier	PMC5952916
has PubMed identifier	29780847
schema:publication	Open Forum Infect Dis
resource representing a document's body	covid:b8991fb0bcc563dc28c736e05639bc604f611e84#body_text
is schema:about of	named entity 'RESPIRATORY TRACT INFECTIOUS DISEASE' named entity 'BACKGROUND' named entity 'CLINICAL DATA' named entity 'ACQUIRED' named entity 'FORUM' covid:arg/b8991fb0bcc563dc28c736e05639bc604f611e84 named entity 'INCLUDE' named entity 'PARAMYXOVIRUSES' named entity 'RESPIRATORY' named entity 'SINGLE' named entity 'CENTER' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'MORTALITY' named entity 'PARAMYXOVIRUS' named entity 'ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION' named entity 'EXPERIENCE' named entity 'INFECTION' named entity 'INFECTIOUS DISEASES' named entity 'COMMUNITY' named entity 'FREQUENCY' named entity 'ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION' named entity 'OPEN' named entity 'CAUSE' named entity 'OUTCOME' named entity 'PARAINFLUENZA VIRUS' named entity 'SIGNIFICANT' named entity 'HUMAN METAPNEUMOVIRUS' named entity 'parainfluenza virus' named entity 'respiratory syncytial virus' named entity 'human metapneumovirus' named entity 'RSV' named entity 'Hematopoietic Cell' named entity 'Allogeneic' named entity 'Infectious Diseases' named entity 'fever' named entity 'immunodeficiency' named entity 'conditioning regimen' named entity 'GvHD' named entity 'Nasopharyngeal swabs' named entity 'paramyxovirus' named entity 'coinfections' named entity 'retrospective study' named entity 'adverse events' named entity 'intensive care unit' named entity 'allogeneic' named entity 'virus' named entity 'virus' named entity 'MPV' named entity 'immunodeficiency' named entity 'upper respiratory tract' named entity 'remission' named entity 'overtreatment' named entity 'forced expiratory volume' named entity 'lymphopenia' named entity 'presatovir' named entity 'confidence interval' named entity 'viruses' named entity 'immunodeficiency' named entity 'neutropenia' named entity 'bronchoalveolar lavage' named entity 'coronavirus' named entity 'paramyxoviruses' named entity 'IVIG' named entity 'Palivizumab' named entity 'allogeneic' named entity 'paramyxovirus' named entity 'presatovir' named entity 'vital capacity' named entity 'paramyxovirus' named entity 'mechanical ventilation' named entity 'infection' named entity 'paramyxovirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software